Tamimi Amirhossein, Javid Mona, Sedighi-Pirsaraei Nasrin, Mirdamadi Arian
School of Medicine, Guilan University of Medical Sciences, Rasht, Iran.
Front Med (Lausanne). 2024 Jul 31;11:1420281. doi: 10.3389/fmed.2024.1420281. eCollection 2024.
The growing prevalence of NAFLD and its global health burden have provoked considerable research on possible diagnostic and therapeutic options for NAFLD. Although various pathophysiological mechanisms and genetic factors have been identified to be associated with NAFLD, its treatment remains challenging. In recent years, exosomes have attracted widespread attention for their role in metabolic dysfunctions and their efficacy as pathological biomarkers. Exosomes have also shown tremendous potential in treating a variety of disorders. With increasing evidence supporting the significant role of exosomes in NAFLD pathogenesis, their theragnostic potential has become a point of interest in NAFLD. Expectedly, exosome-based treatment strategies have shown promise in the prevention and amelioration of NAFLD in preclinical studies. However, there are still serious challenges in preparing, standardizing, and applying exosome-based therapies as a routine clinical option that should be overcome. Due to the great potential of this novel theragnostic agent in NAFLD, further investigations on their safety, clinical efficacy, and application standardization are highly recommended.
非酒精性脂肪性肝病（NAFLD）患病率的不断上升及其全球健康负担引发了对NAFLD可能的诊断和治疗选择的大量研究。尽管已确定多种病理生理机制和遗传因素与NAFLD相关，但其治疗仍然具有挑战性。近年来，外泌体因其在代谢功能障碍中的作用及其作为病理生物标志物的功效而受到广泛关注。外泌体在治疗多种疾病方面也显示出巨大潜力。随着越来越多的证据支持外泌体在NAFLD发病机制中的重要作用，它们的诊疗潜力已成为NAFLD研究的一个关注点。不出所料，基于外泌体的治疗策略在临床前研究中已显示出预防和改善NAFLD的前景。然而，将基于外泌体的疗法作为常规临床选择进行制备、标准化和应用仍面临严峻挑战，这些挑战有待克服。鉴于这种新型诊疗剂在NAFLD中具有巨大潜力，强烈建议对其安全性、临床疗效和应用标准化进行进一步研究。
